11/23/2018 National University of Lesotho, Southern Africa

Slides:



Advertisements
Similar presentations
TB/HIV Research Priorities: TB Preventive Therapy.
Advertisements

Allison Dunning, M.S. Research Biostatistician
Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.
PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.
Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,
AIDS Turning the Tide Together IAS Satellite: Where the Tide Will Turn: How is Community Level Participation Most Effective in Turning the Tide?
HIV-TB Model: The Botswana experience By E.M. Lungu (UB) M. Kgosimore (BCA) F. Nyabadza (UB) Modeling Disease in Africa Workshop 25 – 27 June 2007, Stellenbosch,
Tuberculosis in the UK 2013 report
Unit 5: IPT Isoniazid TB Preventive Therapy
A cost-effectiveness evaluation of preventive interventions for HIV-TB in Sub-Saharan Africa (Tanzania): Relevance for neurological infections Lucie Jean-Gilles.
Effectiveness of Micronutrient-rich Lipid Nutrient Supplements in Delaying Clinical Progression of HIV in Malawian Adults Heidi Sandige, MD.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
Outcomes among patients treated for tuberculosis in Limpopo Province, South Africa, Mmakgotso Pilane, Lazarus Kuonza, Eric Maimela.
Isoniazid preventive therapy for people living with HIV: Public health challenges and implementation issues Peter Godfrey-Faussett UNAIDS (with thanks.
Challenges of service integration: the TB model Linda-Gail Bekker The Desmond Tutu HIV Centre, Faculty of Health Sciences, University of Cape Town, South.
Johns Hopkins Center for Tuberculosis Research
Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , Kelley Bemis, MPH CDC/CSTE Applied.
Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Arnold School of Public Health Health Services, Policy, and Management 1 Drug Treatment Disparities Among African Americans Living with HIV/AIDS Carleen.
Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners “Thibelo TB” Aurum Health Research LSHTM JHU Gold.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
A Call to Action Children – The missing face of AIDS.
A Survival Comparison between HIV+ U.S.-born Latinos and Foreign-born Latinos in Houston, Texas Raouf Arafat, MD, MPH, Adebowale Awosika- Olumo.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.
Outcome of a Prevention of mother to child transmission (PMTCT ) programme following Implementation of prophylaxis for HIV infected pregnant women in Barbados:
SuPAR and sICAM-1 as Immune Markers for Treatment Response in Ethiopian TB patients with and without HIV co-infection Wegene T. Mekasha ICASA, Addis Ababa.
TB-HIV Last updated: January 2017.
Incidence of tuberculosis in the first year of antiretroviral treatment in West-African HIV-infected adults B. Tchakounte Youngui1, P. Coffie2, E. Messou3,
The story of Munya* (and us)
Amir Shroufi Medical Coordinator MSF South Africa
PHASA Conference September 2016
Men are absent across the HIV continuum of care in a rural area of southern Mozambique Laura Fuente-Soro, Elisa Lopez-Varela, Orvalho Augusto , Charfudin.
TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA
I have no conflicts of interest to declare
BREAST CANCER IN SETTING OF HIGH HIV PREVALENCE
Earlier treatment and lower mortality in infants Initiating ART at
Participants 18year old+
Government of Swaziland
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Validating Definitions of Antiretroviral Treatment Failure in Malawi
Simple assessments of adherence to antiretorviral therapy predict virologic failure in HIV+ patients in Lusaka, Zambia Ronald A. Cantrell, MPH University.
Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Clinical outcome after SVR: Veterans Affairs
HIV-associated TB mortality and blocks in the cascade
Dr. Kathure, Weyenga and Langat
TB-HIV Last updated: March 2018.
The use of cotrimoxazole prophylaxis in the context of HIV infection
By: Dr Mirzaei.
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
World Health Organization
Juan Gonzalez Perez AIDS Healthcare Foundation
Pre-conference Meeting Report
TB-HIV Last updated: November 2018.
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.
Knowing your epidemic and knowing your response – maximising routinely collected data to measure and monitor HIV epidemics in sub-Saharan Africa Monitoring.
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Tuberculosis Global Epidemiology
Management and Development for Health (MDH)
Hosted by Joseph Kaunda Alberta Health Services, Canada
Presentation data from US VICTORY Consortium
Preventing recurrent TB in high HIV-prevalent areas
Public Health Implications
Presentation transcript:

11/23/2018 National University of Lesotho, Southern Africa Durability and effectiveness of isoniazid preventive therapy in Lesotho, southern Africa Eltony Mugomeri 22nd International AIDS Conference (AIDS 2018) Amsterdam, Netherlands, 23-27 July 2018 www.aids2018.org

Global TB Hot Spots, 2016 Global Tuberculosis Report (2017) Eltony Mugomeri emugomeri@yahoo.com

Global TB Hot Spots, 2016 Global Tuberculosis Report (2017) Lesotho Eltony Mugomeri emugomeri@yahoo.com

HIV/TB syndemic in sub-Saharan Africa TB incidence, 2016 HIV rates in TB cases, 2016 Global Tuberculosis Report (2017) PLHIV in SSA largest reservoir of TB globally (74% of all annual infections). (Hermans et al, 2016). How effective is universal IPT (all HIV+) in high HIV/TB burden settings? Eltony Mugomeri emugomeri@yahoo.com

HIV/TB syndemic in sub-Saharan Africa TB incidence, 2016 HIV rates in TB cases, 2016 Global Tuberculosis Report (2017) PLHIV in SSA largest reservoir of TB globally (74% of all annual infections). (Hermans et al, 2016). How effective is universal IPT (all HIV+) in high HIV/TB burden settings? Eltony Mugomeri emugomeri@yahoo.com

Provision of IPT to PLHIV, 2005-2014 WHO, 2014 WHO recommended 6 month IPT course for PLHIV in 2004. Sluggish uptake of IPT common in SSA where needed most Eltony Mugomeri emugomeri@yahoo.com

Efficacy of IPT in clinical trials Comstock (1999) Eltony Mugomeri emugomeri@yahoo.com

Efficacy of IPT in clinical trials Optimum IPT course (Clinical Trials) 36 months IPT = 3 yrs protection (Martinson et al, 2009 [S.Africa]; Samandari et al, 2011 [Botswana]). 6 months IPT = 6 months protection (Rangaka et al, 2014) in S. Africa where IPT reduced TB incidence by 60% in HIV+ adults with no history of TB. Rifampicin & pyrazinamide? How effective is universal IPT? Comstock (1999) Eltony Mugomeri emugomeri@yahoo.com

Lesotho’s HIV/TB situation HIV+ = 23.5% (adults) & TB incidence = 852 per 100,000 (WHO, 2016); > 700 per 100,000 alongside S. Africa & Swaziland 74% of TB+ co-infected with HIV (WHO, 2014). TB incidence & notification rates, Lesotho? Eltony Mugomeri emugomeri@yahoo.com

Lesotho’s HIV/TB situation HIV+ = 23.5% (adults) & TB incidence = 852 per 100,000 (WHO, 2016); > 700 per 100,000 alongside S. Africa & Swaziland 74% of TB+ co-infected with HIV (WHO, 2014). TB incidence & notification rates, Lesotho? TB incidence & notification rates, Lesotho? (2000-2013) Eltony Mugomeri emugomeri@yahoo.com

Lesotho’s HIV/TB situation Poor TB treatment outcomes persist TB treatment outcomes (2016) by category (a) and overall (b) (n = 812). Southern African Journal of Infectious Diseases, 33:1, 18-23, Eltony Mugomeri emugomeri@yahoo.com

Lesotho’s HIV/TB situation Poor TB treatment outcomes persist TB treatment outcomes (2016) by category (a) and overall (b) (n = 812). Southern African Journal of Infectious Diseases, 33:1, 18-23, Eltony Mugomeri emugomeri@yahoo.com

Lesotho’s HIV/TB situation Poor TB treatment outcomes persist Defaulted Rx Failure TB treatment outcomes (2016) by category (a) and overall (b) (n = 812). Southern African Journal of Infectious Diseases, 33:1, 18-23, Eltony Mugomeri emugomeri@yahoo.com

Diagnostic techniques for TB in Lesotho Poor scale-up of GeneXpert (Mugomeri et al, 2017) Southern African Journal of Infectious Diseases, 33:1, 18-23, Eltony Mugomeri emugomeri@yahoo.com

METHODS Sampling criteria Stratified systematic random sampling PLHIV (2004 – 2016) from eight district hospitals (three in sparse & five in densely inhabited districts). Eltony Mugomeri emugomeri@yahoo.com

METHODS Data Collection HIV-positive children, adolescents, adults, geriatric & pregnant in 2 cohorts (Before & after IPT launch.) NB. Lesotho launched IPT in 2011. Discrete-time survival data (6-month intervals). Eltony Mugomeri emugomeri@yahoo.com

Data Abstraction Tool Microsoft Access Relational Database Tool (SQL patient profiling) TB Status Key 0 | No TB signs 1 | Active TB 2 | Past TB 3 | TB signs INH Key 1 | Begin IPT 5 | Completed Regimen Key 1f | tenofovir Eltony Mugomeri emugomeri@yahoo.com

METHODS Final sample size Analysis? Eltony Mugomeri emugomeri@yahoo.com

METHODS Final sample size Analysis Cox’s proportional hazard regression model for TB occurrence in Stata® Eltony Mugomeri emugomeri@yahoo.com

RESULTS Rate of initiation on IPT 68.8% of 2,955 sample had received IPT by study exit time (Dec 2016). IPT initiation was 20.6 per 100 person-years, with 135 (6.6%) defaults. Slow IPT initiation? Overall cumulative IPT uptake, 2011-2016 Eltony Mugomeri emugomeri@yahoo.com

RESULTS Rate of initiation on IPT 68.8% of 2,955 sample had received IPT by study exit time (Dec 2016). IPT initiation was 20.6 per 100 person-years, with 135 (6.6%) defaults. Slow IPT initiation: Children/adolescents, higher population density and longer duration of ART>=5 years Overall cumulative IPT uptake, 2011-2016 Eltony Mugomeri emugomeri@yahoo.com

Miss-diagnosis of TB persists TB Miss-diagnosis & IPT side effects still a problem Miss-diagnosis of TB persists Side effects IPT defaulting? Patients in the sparsely populated districts (aOR)=1.6] and males [aOR=2.1] had significantly (p<0.005) higher rates of defaulting IPT compared to those in the densely populated districts and females, respectively. Eltony Mugomeri emugomeri@yahoo.com

Miss-diagnosis of TB persists IPT treatment outcomes Miss-diagnosis of TB persists Side effects IPT defaulting Patients in the sparsely populated districts (aOR)=1.6] and males [aOR=2.1] had significantly (p<0.005) higher rates of defaulting IPT compared to those in the densely populated districts and females, respectively. Eltony Mugomeri emugomeri@yahoo.com

Time to TB event in IPT-exposed cohort Thirty-nine (15.9%, n = 246) patients developed TB after IPT Eltony Mugomeri emugomeri@yahoo.com

Time to TB event in IPT-exposed cohort Miss-diagnosed TB Thirty-nine (15.9%, n = 246) patients developed TB after IPT Eltony Mugomeri emugomeri@yahoo.com

Effectiveness of IPT in Lesotho TB incidences per 100 person-years by timing of IPT: IPT before ART (1.7), IPT after ART (1.8), no IPT (2.6), IPT within one year of ART commencement (1.3) & IPT 3-5 years after ART initiation (2.3). Eltony Mugomeri emugomeri@yahoo.com

Effectiveness of IPT in Lesotho Eltony Mugomeri emugomeri@yahoo.com

Effectiveness of IPT in Lesotho Loss of protection Need to check resistance in cohort? Eltony Mugomeri emugomeri@yahoo.com

Predictor variables for TB event 11/23/2018 Eltony Mugomeri emugomeri@yahoo.com

Predictor variables for TB event Eltony Mugomeri emugomeri@yahoo.com

Significant Predictor variables for TB event Based on Wilcoxon’s log-rank test (Categorical) and Cox regression analysis (Continuous) Gender, Baseline WHO clinical stage, District category, Time to IPT relative to ART commencement (Continuous variable) Eltony Mugomeri emugomeri@yahoo.com

Eltony Mugomeri emugomeri@yahoo.com

Increasing time to IPT by one six-month interval increased the risk of contracting TB by between 6% and 59%, depending on the cohort. NB. Slight variation when factor interaction is considered Eltony Mugomeri emugomeri@yahoo.com

CONCLUSION *Effectiveness of IPT depends on ‘Time to IPT relative to ART commencement’ Ethiopia study: IPT-before-ART (aHR = 0.18, 95% CI = 0.08–0.42) better than simultaneously with ART (aHR = 0.20, 95% CI = 0.10–0.42) (Yardaw et al, 2014) *High risk of reinfection in high TB Burden settings Compared to no IPT, combined IPT and ART reduces the risk of contracting TB by 37% (HR = 0.63, 95 % CI 0.41-0.94) IPT (Rangaka et al. 2014) in S.A; 60 % (HR = 0.40; 95 % CI 0.18 - 0.87) (Ayele et al, 2015) in Ethiopia; Six months IPT = six months protection? (Rangaka et al, 2014) in S. Africa. *Booster doses needed Brazil: Six-month IPT course reduces the risk of contracting TB for at least seven years? Golub et al. (2015)

-Thank You- Acknowledgements D. Olivier and W. M.J. van den Heever National University of Lesotho, Southern Africa -Thank You- Acknowledgements D. Olivier and W. M.J. van den Heever Central University of Technology, Free State, SA “To arrive inductively at laws of [of influence], ... all that is required is a series of careful and exact measures in every different state of the datum and quaesitum.” Herschel in Residuals and Influence in Regresson (Cook & Weisberg, 1982) Eltony Mugomeri emugomeri@yahoo.com